Real-World Characteristics and Treatment Patterns in Patients with Urticaria Initiating Omalizumab in the United StatesXuehua Ke, Lisa A. Beck, Abhishek Kavati et al.|Journal of Managed Care & Specialty Pharmacy|2017Cited by 8
MYC/BCL2 Protein Co-Expression Defines a Unique Subset of Aggressive Lymphoma and Contributes to the Inferior Prognosis of Activated B-cell Subtype of Diffuse Large B-cell Lymphoma: A Report from the International DLBCL Rituximab-CHOP Consortium Program StudyShimin Hu, Ken H. Young, Alexandar Tzankov et al.|Clinical Lymphoma Myeloma & Leukemia|2013Cited by 3